Erythropoietin Receptor on cDC1s Dictates Immune Tolerance

An author correction published in the journal Nature on September 15, 2026, addresses a key finding regarding the erythropoietin receptor (EPOR) and its function on conventional type 1 dendritic cells (cDC1s). The correction specifically clarifies that the EPOR on cDC1s dictates immune tolerance, a crucial aspect of immune system regulation. This finding has significant implications for understanding how the body prevents autoimmune responses and maintains a healthy balance between immunity and self-tolerance.

Dendritic cells, particularly cDC1s, are critical antigen-presenting cells that play a pivotal role in initiating adaptive immune responses. They are responsible for sampling antigens from the environment and presenting them to T cells, thereby shaping the type and magnitude of the immune response. The presence and function of EPOR on these cells suggest a novel pathway through which erythropoietin, a hormone primarily known for its role in red blood cell production, can influence immune cell behavior and immune outcomes. The correction emphasizes that this receptor's activity is directly linked to the establishment and maintenance of immune tolerance, a state where the immune system refrains from attacking the body's own tissues.

Immune tolerance is a complex process that involves multiple mechanisms, including the induction of regulatory T cells and the anergy (unresponsiveness) of self-reactive lymphocytes. Dysregulation of immune tolerance can lead to autoimmune diseases, where the immune system mistakenly targets healthy cells and tissues. Therefore, identifying the molecular players and pathways that govern immune tolerance is of paramount importance for developing new therapeutic strategies for autoimmune conditions such as rheumatoid arthritis, lupus, and type 1 diabetes.

The original research, detailed in the publication with the Digital Object Identifier (DOI) 10.1038/s41586-026-11137-8, likely explored the functional consequences of EPOR signaling in cDC1s. The author correction serves to refine the interpretation of these findings, ensuring scientific accuracy and clarity for the broader research community. By pinpointing the EPOR on cDC1s as a determinant of immune tolerance, this work opens new avenues for investigating how erythropoietin-based therapies or interventions targeting this receptor could potentially be used to modulate immune responses, either to enhance tolerance in autoimmune diseases or to dampen unwanted immune reactions in other contexts. The precise mechanisms by which EPOR signaling on cDC1s translates into tolerance are likely to be a focus of future research, potentially involving downstream signaling cascades that influence cytokine production, T cell activation, or the differentiation of regulatory immune cells.